INTRODUCTION {#sec1-1}
============

Bladder cancer is the 7^th^ most common cancer in men and the 17^th^ most common cancer in women worldwide with an age-standardized incidence of 17 and 6/100,000, respectively.\[[@ref1]\] More than 70% of all bladder cancers are nonmuscle invasive involving only the mucosa and the submucosa.\[[@ref2]\] Mortality of bladder cancer has decreased reflecting an advancing development of new therapeutic approaches.\[[@ref3]\] Standard of care for the treatment of nonmuscle invasive bladder cancer (NMIBC) is transurethral resection (TUR). However, unfortunately, a large percentage of patients do relapse, and many of them progress to muscle invasive disease necessitating radical cystectomy.\[[@ref4]\] The high recurrence and progression rate prompted investigators to use intravesical therapy in an attempt to prevent recurrences. Intravesical *Bacillus* Calmette--Guerin (BCG) has been the standard adjuvant therapy for NMIBC following TUR, showing superiority to many chemotherapeutic agents (doxorubicin and mitomycin-C).\[[@ref5][@ref6]\] Despite this, around 30--45% of patients receiving adjuvant intravesical BCG therapy develop recurrence of their cancer.\[[@ref7]\] Several attempts have been made to reduce the recurrence rate after intravesical BCG therapy. This includes maintenance BCG therapy, combining BCG with other agents such as interferon and the use of other chemotherapeutic agents instead of BCG. We have previously published the result of two investigational approaches to reduce NMIBC recurrence after BCG therapy by either alternating intravesical BCG with interferon on a weekly basis\[[@ref8]\] or combining BCG and Interferon.\[[@ref9]\] Compared to published literature, our results were similar to the results obtained with BCG alone. In this study, we review the result of BCG therapy alone in our institution and compare it to our previously published data of BCG and interferon. In addition, we combine the data of the two groups and evaluate several factors that might affect recurrence.

MATERIALS AND METHODS {#sec1-2}
=====================

The medical records of patients who were treated with intravesical BCG for NMIBC between July 1998 and June 2002 were reviewed. The above period was selected since later on patients were enrolled on multiple prospective investigational trials. Demographic data including age, gender, date of histological diagnosis, recurrent versus de novo tumor, the number of bladder tumors, the size of the largest tumor, concomitant carcinoma *in situ* (Tis), prostatic urethral involvement, and urine cytology were recorded. Data on therapy including baseline blood count, renal and liver function tests, date of TUR, date of the first and last BCG intravesical instillations, number of weekly induction BCG instillations, and reason for stopping short of six instillations if any were recorded. Data on maintenance therapy if given were recorded including the number of courses given (all patients were planned for six maintenance courses per the Southwest Oncology Group \[SWOG\] protocol), reason for stopping maintenance, recurrence rate, and survival. The project was conducted in accordance with the ethical principles contained in the declaration of Helsinki 2013 version,\[[@ref10]\] good clinical practice guidelines and the policies and guidelines of the research advisory council at our institution. Patients identifying data were kept confidential during the study. Tabulation and statistics were done using SPSS statistical program (IBM corporation, Armonk, NY, USA). Survival was calculated using Kaplan--Meier method. Disease-free survival (DFS) was calculated from the date of initiation of therapy till recurrence or death. Progression-free survival was calculated from the date of initiation of therapy till recurrence with a higher stage or death. Overall survival was calculated from the date of initiation of therapy till death. *P* value for survival was calculated using the log-rank method.

Individual patient\'s data were then pooled with our previously reported Phase II trial of concurrent BCG and interferon.\[[@ref9]\] Recurrence and survival were then analyzed for the whole group and according to the treatment cohort (BCG alone and combined BCG and interferon), in addition to factors of possible prognostic importance: Age, gender, number of recurrences, urine cytology, tumor size and number, concurrent Tis, T-stage, T-grade, and maintenance therapy when available.

RESULTS {#sec1-3}
=======

Thirty-one patients were identified with a male to female ratio of 25:6. Median age was 66 years (range: 33--109). Patient\'s characteristics are shown in [Table 1](#T1){ref-type="table"}.

###### 

Patients characteristics-retrospective cohort
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Treatment compliance {#sec2-1}
--------------------

All patients received induction course of BCG with a median of 6 weekly instillation (range 4--6). All patients received the treatment on time except for three who had treatment delays (two for patients request and one because of gross hematuria). Eleven patients underwent maintenance BCG using the SWOG protocol,\[[@ref11]\] with a median of three courses given (3 weekly instillation per course, range 1--6). Eight patients did not complete the maintenance course, three because of patient request, and three because of toxicity, one lost to follow-up and one unknown.

Efficacy {#sec2-2}
--------

A total of 12 patients (38.7%) relapsed over the follow-up period (median 103.5 months, range 46--138.9). Seven of them relapsed at the 3-month evaluation. Stage at the time of relapse was Ta in six patients, T1 in three, and three patients with metastatic disease, two of them were at 3-month evaluation. Five years relapse-free survival for the whole group was 61.3% (95% confidence interval (CI) 44.2--78.4%), progression-free survival was 85.6% (95% CI 73.3--97.9%) (five patients developed metastasis), and overall survival was 93% (95% CI 84.1--100%). Univariate analysis of factors that are known to affect recurrence and progression was performed and showed no significant difference in any subgroup as shown in [Table 2](#T2){ref-type="table"}. However, it is worth noting that patients with Ta tumors had much lower chance of being disease free at 5 years than patients with T1 lesions (38.5 vs. 77.8%) and similarly those who were treated upon recurrence as compared to those who were treated on first presentation (50.0 vs. 72.7%). In addition, none of the patients who had three or less tumors progressed at 5 years.

###### 

Univariate analysis of factors that affect disease-free and progression-free survival for the retrospective cohort and the combined cohort

![](UA-8-333-g002)

Twenty-four patients were disease free at 3 months evaluation and are eligible for analysis of the benefit of maintenance therapy. Out of those, 11 had maintenance therapy. Median relapse-free survival for both groups was not reached, and the difference was not significant with *P* = 0.3. Reasons for stopping maintenance varied from failure to follow-up in two patients, patient refusal in three, and severe toxicity in three.

Pooled data of our retrospective analysis and prospective Phase II trial comprised a total of 81 patients (31 retrospective and fifty prospective). Univariate analysis of DFS was performed according to the treatment received number of tumors (≤3 or \>3), single or multiple tumors, T-stage (Ta vs. T1), and tumor grade (Grade 1 vs. 2 vs. 3). No significant difference was found in any of the above factors \[[Table 3](#T3){ref-type="table"}\].

###### 

Univariate analysis of factors that affect recurrence in pooled patients' data
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DISCUSSION {#sec1-4}
==========

We have previously reported the result of post-TUR therapy for NMIBC with the combination of BCG and interferon given in a context of Phase II trial and compared it with international historical control.\[[@ref9]\] This study is the first and only one from Saudi Arabia to report the result of BCG prophylaxis in the prevention of recurrence of superficial bladder cancer.

Our study confirms similar efficacy of BCG in the prophylaxis of recurrence of NMIBC in a retrospectively studied cohort compared to published literature. Our 5-year relapse-free survival of 61.8% was similar to the results seen with different Phase III trials using BCG alone and meta-analysis of BCG therapy.\[[@ref12][@ref13][@ref14]\] This is seen despite that 58.1% of the patient has T1 tumors, 45% have more than three tumors, and the majority (64.3%) were recurrent rather than primary presenting tumors.

We have looked at several factors that affect the result of therapy with BCG. Of these, the issue of maintenance therapy remains controversial. Out of five maintenance trials,\[[@ref15][@ref16][@ref17][@ref18]\] the SWOG trial was the only one which showed a significant benefit over no maintenance therapy.\[[@ref11]\] Despite this, several meta-analysis has confirmed the improved results with maintenance therapy.\[[@ref5][@ref19][@ref20][@ref21]\] In our study, there was no difference in DFS at 5 years between maintenance versus no maintenance groups (81.8 vs. 76.9, respectively, *P* = 0.3). This is likely secondary to the small number of patients in the study and the retrospective nature of it. Three of the 11 maintenance patients in our study (27%) completed the full course compared to 18% reported in the SWOG trial, confirming the difficulty in finishing maintenance therapy. This is mainly secondary to toxicity. Other factors previously identified that affect recurrence or progression include treatment on the first presentation versus recurrence, number of tumors on presentation, tumor stage (Ta vs. T1), tumor grade, positive urine cytology, and maximum tumor size.\[[@ref22][@ref23]\] Our data showed no significant difference in recurrence and progression-free survival among patients with primary presentation versus recurrence, patients with more than three tumors versus less, likely secondary to small number. Although not significant, it is interesting to know that our study showed a superior 5 year DFS (77.8% vs. 38.5%) but equal 5-year PFS (87.4% vs. 84.6%) for patients with T1 compared to those with Ta lesions, respectively. It is important to note that in view of the retrospective nature of the study, data like urine cytology and tumor size were not consistently available and accordingly were not included in the analysis.

Finally, the combined analysis confirms the equal efficacy of BCG alone versus combined BCG and Interferon as has been concluded and reported in our previously published Phase II trial.\[[@ref9]\]

CONCLUSION {#sec1-5}
==========

Our study shows similar results for the use of BCG in the prevention of recurrence of NMIBC, compared to published literature. In addition, it confirms that combining BCG with interferon does not add to its efficacy in first-line management.
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